EyePoint Pharmaceuticals saw its stock collapse by 86% on Tuesday after the company announced it was ending its pivotal phase 3 trials for wet age-related macular degeneration (wet AMD) and slashing its workforce by 53%. The move marks a dramatic reset for a biotech that had been betting its future on a single late-stage program.
What happened
EyePoint said it would not complete the second year of its two phase 3 studies for its wet AMD treatment. These trials were the company's most advanced clinical programs and were seen as the primary path to regulatory approval. Alongside the trial halt, the company announced deep layoffs, cutting more than half of its staff to preserve cash.
Late-stage clinical trials are a biotech's closest thing to a finish line. They are costly, take years to run, and are often the main evidence regulators require before a drug can be approved. Ending them early is a major setback, and investors reacted swiftly. The stock dropped 86% on volume of about 161 million shares, compared with roughly 4 million on a typical day. That kind of volume spike suggests a fast repricing: many shareholders headed for the exit while a new, more speculative investor base stepped in.
Why it matters for investors
When a company ends a pivotal phase 3 program early, the market often stops valuing it like a probability-weighted launch and starts valuing it around survival and options: what assets are left, and how they get funded. With the trial timeline pushed out or potentially removed as a clear catalyst, EyePoint's leverage in raising cash usually weakens. That can mean issuing shares at a steep discount, using an at-the-market (ATM) offering, selling convertible debt, or signing a partnership on less favorable terms.
The massive trading volume also points to a shareholder-base reset. That can keep volatility high and make future updates trade less on scientific nuance and more on what they signal about runway and fundraising terms. For everyday investors, the key takeaway is that EyePoint is now a much riskier proposition. The company's near-term story has been rewritten, and its ability to continue as a going concern will depend on how it manages its cash and whether it can find new financing or partners.
Broader biotech context
EyePoint's crash is not happening in a vacuum. The biotech sector has been under pressure recently, with some analysts warning that the rally in biotech stocks is losing steam as catalysts dry up. A recent note from BofA highlighted that many small-cap biotechs are running out of near-term catalysts, which can lead to sharp selloffs when trials fail or are discontinued.
Other biotech setbacks have also weighed on the sector. For instance, a biotech ETF slid 2.6% after Omeros and MDxHealth tumbled on their own clinical and regulatory setbacks. These events underscore the high-risk, high-reward nature of biotech investing, where a single trial outcome can make or break a company.
Despite the gloom, there are bright spots. Healthcare stocks rallied recently as AstraZeneca and Labcorp deals lifted biotech sentiment, showing that the sector can still attract capital when there are clear opportunities. But for companies like EyePoint, the path forward is now much more uncertain.
What to watch next
Investors will be watching EyePoint's next moves closely. The company will need to communicate how it plans to fund its operations and whether it will pursue a strategic alternative, such as a sale or partnership. The layoffs suggest management is trying to stretch its cash runway, but with the main clinical program halted, the company's long-term viability is in question.
For those holding EyePoint shares, the immediate focus should be on the company's cash position and any announcements about financing. For the broader market, this episode is a reminder of the binary nature of biotech investing: a single trial can send a stock soaring or crashing. As always, diversification and a clear understanding of the risks are essential for anyone considering investments in this space.
